A Study of SGN-STNV in Advanced Solid Tumors

NCT04665921 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

111

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Carcinoma, Non-Small Cell Lung
HER2 Negative Breast Neoplasms
Ovarian Neoplasms
Uterine Cervical Neoplasms
Endometrial Neoplasms
Esophageal Neoplasms
Gastroesophageal Junction Carcinoma
Stomach Neoplasms
Colorectal Neoplasms
Exocrine Pancreatic Adenocarcinoma
Appendiceal Adenocarcinoma
Pseudomyxoma Peritonei

Interventions

DRUG: SGN-STNV

Sponsor

Seagen Inc.